In Westlaw Today, Health Care Attorneys Examine Executive Order for Most-Favored-Nation Prescription Drug Pricing

In a Westlaw Today article, health care partner Margaux Hall, who leads the firm’s drug pricing and pricing reporting group, and health care associate Sarah Barth examined the executive order directing executive agencies to impose targets on drugmakers to provide most-favored-nation (MFN) prescription drug pricing to U.S. patients so they do not pay more than patients elsewhere.

The authors note the executive order does not provide further detail regarding how the U.S. Department of Health and Human Services and the Assistant to the President for Domestic Policy will go about setting MFN targets, what constitutes "significant progress" towards those targets, or the specific nature or timing of penalties for failing to reach the targets.